U.S. Markets open in 1 hr 20 mins

Halozyme Therapeutics, Inc. (HALO)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
12.10+0.20 (+1.68%)
At close: 4:00PM EDT
People also watch
ZIOPFOLDACADCLDXACHN
  • B
    BioNap
    BioNap

    SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $18 Million
    Cash: $8 Million
    Price $0.37

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • P
    Paul
    Paul
    This is what HALO produces from top to bottom! Dilution coming once again!
    Imagecrap-userrname16
  • p
    pops or homo
    pops or homo
    how low will this go charties
  • E
    Eric1987
    Eric1987
    Royalties alone are up 20%! from last year .. come on guys
  • E
    Eric1987
    Eric1987
    The Earnings report was WAY better then what everyone here was thinking AKA the shorts... This has WINNER all over it. next JNJ. $$
  • S
    Sandy
    Sandy
    Will be trading back in the single digits soon.
  • S
    Sandy
    Sandy
    Keep shorting this Pig
  • M
    Michael
    Michael
    Just the usual. Low royalties. Huge expenditure. No news and basically nothing due. This is going down.
  • p
    paul
    paul
    Check your monthly chart. I would be surprised if 12.26 is not the bottom.
  • M
    Michael
    Michael
    More of the same today no doubt. Disappointing partner royalties - are Shire selling any HyQ? Huge expenditure mainly on the endless PEG trials. Yet again no news on those trials - whatever happpened to the promised interim readouts on the
  • J
    JANET
    JANET
    I find it interesting that Halo has not commented on or updated their website of the addition of Rituxan Hycela as a product they are part of. I was worried about this, but found it advertised on Genentech. I would have thought they would have at least updated their website. Any thoughts?
  • M
    MARK
    MARK
    Way oversold,they're hiring on a weekly basis.Something big in the woks
  • G
    George
    George
    earnings tomorrow, should be interesting................present on Thursday, maybe stock poised for a little run, would be nice.
  • P
    Paul
    Paul
    Eat dung HALO! Bwahahahahaha!
    Imagepareidoliaaa
  • G
    George
    George
    Shorts have it right now, should go to $10 after earnings, but still have drugs in the pipeline, will be short term pain, will lose 30% or so and then get back to $12 by end of year.
  • R
    Rodrique
    Rodrique

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • S
    Sandy
    Sandy
    Many other biotechs reaching New highs with a promising line of drugs while HALO usvstuck in the doldrums.
  • S
    Sandy
    Sandy
    Punish the monkey.
  • C
    Crecy
    Crecy
    HALO, ... Hummmmmm..........you guys watch AVEO today? It's heading to $4 on a Recommendation for Approval of it's Renal Cancer drug Tivo,, Approval day is SOON, end of Aug. Still time to ACCUMULATE.
  • G
    George
    George
    bio-tech stocks trade on FDA approvals, not quarterly earnings reports, unless stock in money woes, the earnings are meaningless, it is what is in the pipeline.